✦ LIBER ✦

Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

✍ Scribed by C. Twelves; K. Hoekman; A. Bowman; J.B. Vermorken; A. Anthoney; J. Smyth; C. van Kesteren; J.H. Beijnen; J. Uiters; J. Wanders; J. Gomez; C. Guzmán; J. Jimeno; A. Hanauske

Book ID: 117660147
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 279 KB
Volume: 39
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(03)00458-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

550 Phase I and pharmacokinetic (PK) stu

550 Phase I and pharmacokinetic (PK) study of trabectedin (ET-743) administered as a 1-hour infusion weekly for 3 consecutive weeks every 4 weeks to patients with advanced cancer

✍ S.Q. Chu; G. Schwartz; M. Beeram; A. Patniak; M. Mita; J. Jimeno; L. Lopez-Laraz 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 273 KB

A phase 1 study of OSI-211 given as an i

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

✍ K. Gelmon; H. Hirte; B. Fisher; W. Walsh; M. Ptaszynski; M. Hamilton; N. Onetto; 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 283 KB

Phase I clinical and pharmacokinetic stu

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

✍ C Terret; S Zanetta; H Roché; J.H.M Schellens; M.N Faber; J Wanders; M Ravic; J. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 218 KB

27 ORAL Phase I dose escalation study of

27 ORAL Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 6-hour infusion on days 1, 8 and 15 every 4 weeks in patients with advanced/metastatic solid tumors

✍ M. De Jonge; N. Steeghs; J. Verweij; J.W.R. Nortier; F. Eskens; J. Ouwerkerk; C. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 82 KB

A phase I pharmacokinetic (PK) and seria

A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 256 KB